Abstracts Archive - Page 2135 of 2425 - ACR Meeting Abstracts

Abstract Number: 1767 • 2013 ACR/ARHP Annual Meeting
Gender, Race, and Soluble Mediators Distinguish Blood Relatives Who Develop Incomplete Lupus Or Classified SLE In The Lupus Autoimmunity In Relatives (LAUREL) Study
Melissa E. Munroe¹, Kendra A. Young², Jill M. Norris², Joel M. Guthridge³, Diane L. Kamen⁴, Timothy B. Niewold⁵, Gary S. Gilkeson⁴, Michael H. Weisman⁶, Mariko L. Ishimori⁶, Daniel J. Wallace⁷, David R. Karp⁸, John B. Harley^9,10 and Judith A. James^11,12, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁵Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ⁹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and identify individuals for prevention trials. Healthy blood relatives (FDRs) of lupus…
Abstract Number: 1728 • 2013 ACR/ARHP Annual Meeting
Amelioration Of Collagen-Induced Arthritis By Modulation Of Inhibitory Apoptosis Stimulating Protein Of p53 To Activate Transcription Factor p73
Chrong-Reen Wang¹, Shih-Yao Chen², Ai-Li Shiau³, Yuan-Tsung Li⁴, Chia-Tse Weng⁵, I-Ming Jou⁶, Ming-Fei Liu⁷ and Chao-Liang Wu², ¹Section of Rheumatology and Immunology, Department of Internal Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ²Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan, ³Microbiology and Immunology, National Cheng Kung University Medical College, Tainan, Taiwan, ⁴Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ⁵Internal Medicine, National Cheng Kung University Medical College, Tainan, Taiwan, ⁶Orthopedics, National Cheng Kung University Medical College, Tainan, Taiwan, ⁷Internal Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
Background/Purpose: Our previous studies have demonstrated p53 mutations competent for the inactivation of wild type p53 in synovial fibroblasts (SF) from either rheumatoid arthritis patients…
Abstract Number: 1729 • 2013 ACR/ARHP Annual Meeting
Cell Cycle Regulation Therapy Combined With Cytokine Blockade Enhances Anti-Arthritic Effects Without Increase Of Immune Suppression
Tadashi Hosoya¹, Hideyuki Iwai¹, Yu Yamaguchi², Nobuyuki Miyasaka² and Hitoshi Kohsaka², ¹Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ²Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is characterized by infiltration of immune cells to the synovial tissues and their hyperplasia. Aim of the current…
Abstract Number: 1730 • 2013 ACR/ARHP Annual Meeting
Novel Role For Ly6C^– Monocyte Subsets and Joint Macrophages In Mouse Model Of Rheumatoid Arthritis
Alexander Misharin¹, Carla M. Cuda², Rana Saber³, Angelica K. Gierut⁴, G. Kenneth Haines III⁵, Steffen Jung⁶ and Harris R. Perlman⁷, ¹Medicine, Division of Rheumatology, Northwestern University, Chicago, IL, ²Medicine / Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Medicine/Rheumatology, Northwestern University, Chicago, IL, ⁴Rheumatology, Northwestern Med Faculty Found, Chicago, IL, ⁵Department of Pathology, Yale University, New Haven, CT, ⁶Immunology, Weizmann Institute, Rehovot, Israel, ⁷Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Monocytes and macrophages play a key role in the pathogenesis of rheumatoid arthritis. However, role of the individual subsets of monocytes and macrophages in…
Abstract Number: 1731 • 2013 ACR/ARHP Annual Meeting
Treatment Of Innate Immune Arthritis With a Toll-Like Receptor 7 Agonist Requires Type I Interferon
Maripat Corr¹, Tomoko Hayashi², Dennis A. Carson³, Howard Cottam⁴ and Joshua Yang³, ¹Medicine, Univ of California-San Diego, La Jolla, CA, ²Medicine, UCSD School of Medicine, La Jolla, CA, ³UCSD School of Medicine, La Jolla, CA, ⁴ucsd School of Medicine, La Jolla, CA
Background/Purpose: We previously demonstrated that repeated administration of the low molecular weight Toll-like receptor (TLR) 7 agonist (1V136) substantially reduces arthritic inflammation in mice. Here…
Abstract Number: 1732 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Subcutaneous Administration Of Tabalumab, An Anti-B Cell Activating Factor Monoclonal Antibody, In Rheumatoid Arthritis: Results From a Phase 3 Multicenter, Randomized, Double-Blind Study
MC Genovese¹, Gregg J. Silverman², Paul Emery³, Ramesh Gupta⁴, Anne Gill⁵, Wendy J. Komocsar⁵, Melissa Veenhuizen⁵, Li Xie⁵, Pierre-Yves Berclaz⁵ and Chin Lee⁵, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Rheumatology, NYU School of Medicine, New York, NY, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Private Practice, Memphis, TN, ⁵Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Tabalumab is a monoclonal antibody that neutralizes membrane-bound and soluble B cell activating factor (BAFF). These interim analyses evaluated the efficacy and safety of…
Abstract Number: 1733 • 2013 ACR/ARHP Annual Meeting
Early and Sustained Improvement In Pain and Physical Function As Measured By Visual Analog Scale and Short Form-36 Physical Component Summary Score In Rheumatoid Arthritis Patients Treated With Mavrilimumab, An Investigational Anti-GM-CSFR-Alpha Monoclonal Antibody, In a Phase 2a Study
Gerd Burmester¹, Tsutomu Takeuchi², Olga Barbarash³, Duncan Porter⁴, Didier Saurigny⁵, David Close⁵, Alex Godwood⁵, Yoojung Yang⁶ and Ancilla W. Fernandes⁶, ¹Rheumatology and Clinical Immunology, Campus Mitte, Charite University Hospital, Berlin, Germany, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³SIH Kemerovo Regional Clinical Hospital, Kemerovo, Russia, ⁴Rheumatology, Gartnavel General Hospital, Glasgow, United Kingdom, ⁵MedImmune, Ltd, Cambridge, United Kingdom, ⁶MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Rheumatoid arthritis (RA) is associated with significant pain and loss of physical function. We evaluated self-reported pain and physical function in adults patients with…
Abstract Number: 1734 • 2013 ACR/ARHP Annual Meeting
A Phase Ib Clinical Trial With Dekavil (F8-IL10), An Immunoregulatory ‘Armed Antibody’ For The Treatment Of Rheumatoid Arthritis, Used In Combination With Methotrexate
M. Galeazzi¹, L Bazzichi², E Prisco³, G D Sebastiani⁴, D. Neri⁵, L Giovannoni⁶, F Bacchion⁷, M Bardelli¹, C Baldi¹, E Selvi¹, G Minisola⁸, R Caporali⁹ and S Bombardieri¹⁰, ¹Rheumatology Unit, University Hospital of Siena, Siena, Siena, Italy, ²Division of Rheumatology, University of Pisa, Pisa, Pisa, Italy, ³Rheumatology, Deptartment of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Pavia, Italy, ⁴Rheumatology Unit, San Camillo-Forlanini Hospital, Rome, Rome, Italy, ⁵Chemistry and Applied Sciences, Swiss Federal Institute of Technology, Zurich, Zurich, Switzerland, ⁶Clinical Research Unit, Philogen S.p.A., Siena, Sovicille - (SI), Italy, ⁷Clinical Research Unit, Philogen S.p.A, Siena, Sovicille - (SI), Italy, ⁸Rheumatology Unit, San Camillo-Forlanini Hospital, Rome, Rome, Italy, ⁹Department of Rheumatology, University of Pavia, IRCSS Policlinico San Matteo Foundation, Pavia, Pavia, Italy, ¹⁰Department of Clinical and Experimental Medicine, Department of Rheumatology, University of Pisa, Pisa, Pisa, Italy
Background/Purpose: A therapeutic strategy based on the selective delivery of an immuno-regulatory cytokine to the sites of inflammatory disease has been developed. DEKAVIL is an…
Abstract Number: 1735 • 2013 ACR/ARHP Annual Meeting
A Phase IIb Study Of The Efficacy and Safety Of Subcutaneous Clazakizumab (anti-IL-6 monoclonal antibody) With Or Without Methotrexate In Adults With Moderate-To-Severe Active Rheumatoid Arthritis and An Inadequate Response To Methotrexate
M Weinblatt¹, Philip Mease², E Mysler³, T Takeuchi⁴, E Drescher⁵, A Berman⁶, M Zilberstein⁷, J Xing⁷ and P Emery⁸, ¹Brigham and Women's Hospital, Boston, MA, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Organización Médica de Investigación, Buenos Aires, Argentina, ⁴Keio University, Tokyo, Japan, ⁵Csolnoky Ferenc Hospital, Veszprém, Hungary, ⁶Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸University of Leeds, Leeds, United Kingdom
Background/Purpose: Clazakizumab (claza) is a humanized anti-interleukin-6 (IL-6) monoclonal antibody that potently neutralizes IL-6 signaling. This study evaluated the safety and efficacy of subcutaneous claza…
Abstract Number: 1736 • 2013 ACR/ARHP Annual Meeting
A Randomized, Controlled, Multicenter, 2‑Arm, Parallel‑Group, Double-Blind Study To Demonstrate The Equivalence Of CT-P10 To Innovator Rituximab With Respect To Pharmacokinetic Profile In Patients With Rheumatoid Arthritis
Dae-Hyun Yoo¹, Won Park², Slawomir Jeka³, Fidencio Cons Molina⁴, Pawel Hrycaj⁵, Piotr Wiland⁶, Wolfgang Spieler⁷, Jan Brzezicki⁸, Eun Young Lee⁹, Francisco G. Medina-Rodriguez¹⁰, Pavel Shesternya¹¹, Sebastiao Radominski¹², Marina Stanislav¹³, Volodymyr Kovalenko¹⁴, Dong Hyuk Sheen¹⁵, Mie Jin Lim¹⁶, Jung-Yoon Choe¹⁷, Sung Young Lee¹⁸, Seung-Cheol Shim¹⁹ and Chang-Hee Suh²⁰, ¹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ³Clinic of Rheumatology and Connective Tissue Diseases University Hospital No 2 in Bydgoszcz Collegium Medicum UMK in Torun, Bydgoszcz, Poland, ⁴Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, ⁵Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, ⁶Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ⁷Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁸Wojewodzki Szpital Zespolony Oddzial Reumatologiczny, Elblag, Poland, ⁹Internal medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ¹⁰Centro de Investigación Farmacológica y Biotecnológica, Mexico City, Mexico, ¹¹Rheumatology Department, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, ¹²CETI Centro de Estudos em Terapias Inovadoras Ltda, Curitiba, Brazil, ¹³Central Russian National Institute of Rheumatology, Russian Academy of Medical Science, Moscow, Russia, ¹⁴Section of Non-coronarogenic Myocardial Diseases and Clinical Rheumatology, National Scientific Center, Kiev, Ukraine, ¹⁵Rheumatology, Eulji University Hospital, DaeJeon, South Korea, ¹⁶Division of Rheumatology, Department of Internal Medicine,, Inha University Hospital, Incheon, South Korea, ¹⁷Rheumatology, Daegu Catholic University Medical Center, Daegu, South Korea, ¹⁸Clinical Planning and Medical Affairs Department, CELLTRION, Inc., Incheon, South Korea, ¹⁹Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, ²⁰Department of Rheumatology, Ajou University Hospital, Suwon, South Korea
Background/Purpose: CT-P10 was developed as a biosimilar candidate to innovator rituximab (RTX), an anti-CD20 monoclonal antibody. This trial is a phase I study to demonstrate…
Abstract Number: 1737 • 2013 ACR/ARHP Annual Meeting
Association Of HLA-DRB1 Alleles With Clinical Responses To The Anti-Interleukin−17A Monoclonal Antibody Secukinumab In a Cohort Of Patients With Active Rheumatoid Arthritis: An Exploratory Phase 2 Biomarker Study
Gerd Burmester¹, Patrick Durez², Galina Shestakova³, Yue Li⁴, Amanda Wang⁵, Steve Lewitzky⁵, Irina Koroleva⁵, David Lee⁶ and Wolfgang Hueber⁷, ¹Department of Rheumatology & Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, ²Université Catholique de Louvain, Brussels, Belgium, ³Kaluga State Pedagogical Tsiolkovsky University, Kaluga, Russia, ⁴IIS, Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharma AG, Cambridge, MA, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Translational Medicine Autoimmunity, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: The shared epitope (SE) may play a functional role in RA via Th17/interleukin (IL)-17 polarization (Holoshitz et al. FEBS Lett 2011;585:3619-26). Two phase 2…
Abstract Number: 1738 • 2013 ACR/ARHP Annual Meeting
Epratuzumab Maintains Improvements In Disease Activity For Over 2 Years In Patients With Moderate-To-Severe Systemic Lupus Erythematosus: Results From An Open-Label Long-Term Extension Study
Megan E. B. Clowse¹, Frederic Houssiau², Michelle A. Petri³, Brian Kilgallen⁴, Kenneth Kalunian⁵, Vibeke Strand⁶, Sabine Bongardt⁷, Caroline Gordon⁸ and Daniel J. Wallace⁹, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Department of Rheumatology, Université catholique de Louvain, Brussels, Belgium, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴UCB Pharma, Smyrna, GA, ⁵UCSD School of Medicine, La Jolla, CA, ⁶Stanford University, Palo Alto, CA, ⁷UCB Pharma, Brussels, Belgium, ⁸Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, ⁹Rheumatology, Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Epratuzumab is a monoclonal antibody targeting CD22. In EMBLEMTM (dose-ranging phase IIb study), epratuzumab produced clinically relevant improvements in disease activity in patients…
Abstract Number: 1739 • 2013 ACR/ARHP Annual Meeting
Sustained British Isles Lupus Assessment Group-Measured Improvement In Moderately-and-Severely Affected Body Systems In Patients With Systemic Lupus Erythematosus By Epratuzumab: Results From An Open-Label Extension Study
Kenneth Kalunian¹, Megan E. B. Clowse², Frederic Houssiau³, Michelle A. Petri⁴, Brian Kilgallen⁵, Caroline Gordon⁶, Vibeke Strand⁷, Sabine Bongardt⁸ and Daniel J. Wallace⁹, ¹UCSD School of Medicine, La Jolla, CA, ²Rheumatology, Duke University Medical Center, Durham, NC, ³Department of Rheumatology, Université catholique de Louvain, Brussels, Belgium, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵UCB Pharma, Raleigh, NC, ⁶Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, ⁷Stanford University, Palo Alto, CA, ⁸UCB Pharma, Brussels, Belgium, ⁹Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Epratuzumab is a monoclonal antibody targeting CD22. In EMBLEMTM (a dose-ranging phase IIb study), epratuzumab produced clinically relevant improvements in disease activity in patients…
Abstract Number: 1740 • 2013 ACR/ARHP Annual Meeting
12-Month Outcomes Associated With Belimumab In Patients With Systemic Lupus Erythematosus In Clinical Practice Settings: The Observe Study
Christopher E. Collins¹, Maria Dall'era², Alan Oglesby³, Michael B. McGuire⁴, Ramesh Pappu³, Hong Kan³ and Charles T. Molta⁵, ¹Rheumatology, Washington Hospital Center, Washington, DC, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ³GlaxoSmithKline, Research Triangle Park, NC, ⁴Medical Data Analytics, Parsippany, NJ, ⁵GlaxoSmithKline, King of Prussia, PA
Background/Purpose: Large-scale clinical trials have demonstrated the clinical efficacy of belimumab in patients with systemic lupus erythematosus (SLE). We examined clinical outcomes associated with 12…
Abstract Number: 1741 • 2013 ACR/ARHP Annual Meeting
Correlation Of The Interferon Gene Signature With Systemic Lupus Erythematosus Disease Activity Is Dependent On The Associated Level Of The BAFF Gene Transcript
Michelle Petri¹, Laurence S. Magder², Hong Fang¹, Julie Czerkowicz³, Andrea Dearth³, Jadwiga Bienkowska⁴, Norm Allaire⁵, Patrick Cullen³, Alice Thai³ and Ann Ranger³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Biogen Idec Inc, Cambridge, MA, ⁴Translational Medicine, Biogen Idec Inc., Cambridge, MA, ⁵Biogen Idec Inc., Cambridge, MA
Background/Purpose: The interferon alpha (IFN) gene signature is frequent in SLE (~50% of patients) and important in pathogenesis. However, multiple studies have found that the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].